Plain-English translation of NCT07039162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called combined with radiation therapy and chemotherapy for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) that cannot currently be removed by surgery. The goal is to see if this combination treatment can shrink the cancer enough to make it operable, and ultimately improve how long patients survive. Researchers will track how well the treatment works, how safe it is, and whether surgery becomes possible after the initial therapy.
Esophageal cancer that has grown into nearby organs or spread to lymph nodes is very difficult to treat and has a poor outlook with standard therapies alone. This trial is exploring whether adding this immunotherapy medication to existing treatments can improve outcomes by helping the body's immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would first receive induction chemoradiotherapy (radiation combined with chemotherapy drugs) along with the new immunotherapy medication, delivered over several weeks. After that, you would receive two additional cycles of the immunotherapy with chemotherapy to consolidate the response. If your tumor shrinks enough to become surgically removable, you would then undergo surgery to remove it. Throughout the trial, you would have regular blood tests, imaging scans, and clinic visits to monitor your response and any side effects from treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Taiwan